{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-171124","form_type":"8-K","ticker":"RXRX","cik":"0001601830","company_name":"RECURSION PHARMACEUTICALS, INC.","filed_at":"2022-06-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.431495+00:00","generated_at":"2026-06-25T03:10:11.492597+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Recursion Pharmaceuticals: CMO Ramona Doyle departs; Shafique Virani appointed interim CMO","bullets":["Ramona Doyle's employment as CMO ended June 7, 2022.","Shafique Virani appointed interim CMO, effective June 7, 2022.","Virani continues to serve as chief business officer.","Virani previously served as interim CMO from March to December 2020.","Virani joined Recursion in March 2020; prior roles included CEO of BridgeBio subsidiaries."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-171124","json":"https://secwatch.observer/filing/0001193125-22-171124.json","markdown":"https://secwatch.observer/filing/0001193125-22-171124.md","text":"https://secwatch.observer/filing/0001193125-22-171124.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1601830/000119312522171124/0001193125-22-171124-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1601830/000119312522171124/d272982d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T03:10:11.492597+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"490897c01c","claim":"Ramona Doyle departed as Chief Medical Officer at RECURSION PHARMACEUTICALS, INC..","evidence_excerpt":"The employment of Ramona Doyle, MD as chief medical officer (“CMO”) of Recursion Pharmaceuticals, Inc. (the “Company”) ended on June 7, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1601830/000119312522171124/0001193125-22-171124-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ended"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"63170739b8","claim":"Shafique Virani was appointed as interim Chief Medical Officer at RECURSION PHARMACEUTICALS, INC..","evidence_excerpt":"Also, on June 7, 2022, the Company appointed Shafique Virani, MD FRCS, as interim CMO.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1601830/000119312522171124/0001193125-22-171124-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"interim Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}